162 related articles for article (PubMed ID: 38697960)
21. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
22. Predictive Factors and Outcomes after Allogeneic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia in Brazil.
Silva WF; Cysne DN; Kerbauy MN; Colturato I; Maia ACA; Tucunduva L; Barros GMN; Colturato VAR; Hamerschlak N; Rocha V
Transplant Cell Ther; 2022 Nov; 28(11):763.e1-763.e7. PubMed ID: 35914726
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
24. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
[TBL] [Abstract][Full Text] [Related]
25. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
26. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
[TBL] [Abstract][Full Text] [Related]
27. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
[TBL] [Abstract][Full Text] [Related]
29. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
Poiré X; Labopin M; Cornelissen JJ; Volin L; Richard Espiga C; Veelken JH; Milpied N; Cahn JY; Yacoub-Agha I; van Imhoff GW; Michallet M; Michaux L; Nagler A; Mohty M
Am J Hematol; 2015 Aug; 90(8):719-24. PubMed ID: 26010466
[TBL] [Abstract][Full Text] [Related]
30. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
33. Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Rank A; Peczynski C; Labopin M; Stelljes M; Simand C; Helbig G; Finke J; Santarone S; Tischer J; Lange A; Mistrik M; Houhou M; Schmid C; Nagler A; Mohty M
Transplant Cell Ther; 2021 May; 27(5):408.e1-408.e6. PubMed ID: 33965180
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
[TBL] [Abstract][Full Text] [Related]
35. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
[TBL] [Abstract][Full Text] [Related]
36. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
[TBL] [Abstract][Full Text] [Related]
38. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
Santoro N; Labopin M; Giannotti F; Ehninger G; Niederwieser D; Brecht A; Stelljes M; Kröger N; Einsele H; Eder M; Hallek M; Glass B; Finke J; Ciceri F; Mohty M; Ruggeri A; Nagler A
J Hematol Oncol; 2018 Apr; 11(1):55. PubMed ID: 29661208
[TBL] [Abstract][Full Text] [Related]
39. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
[TBL] [Abstract][Full Text] [Related]
40. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.
Sengsayadeth S; Labopin M; Boumendil A; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gatwood KS; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1406-1414. PubMed ID: 29678639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]